Abstracts tagged "Bisphosphonates"

Abstract Number: 839 • 2017 ACR/ARHP Annual Meeting
Use of Bisphosphonate and Risk of Incident Atrial Fibrillation in a Population-Based Study
Shanshan Sheehy¹, Christine Peloquin² and Tuhina Neogi³, ¹Clinical Epidemiology Research & Training Unit, Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Bisphosphonates remain the first-line agent prescribed medication for the prevention and treatment of osteoporosis. Apart from concern about atypical fractures, another concern about risk…
Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Mikala C. Osani¹, Elizaveta Vaysbrot¹, Raveendhara R. Bannuru², Mia-Cara Musetti¹ and Timothy E. McAlindon¹, ¹Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…
Abstract Number: 1212 • 2017 ACR/ARHP Annual Meeting
Relation of Incident Bisphosphonate Use to Bone Marrow Lesion Volume in Knee Osteoarthritis
Tuhina Neogi¹, Jeffrey Duryea², Na Lu¹, Jingbo Niu¹ and Yuqing Zhang¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Radiology, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Bone marrow lesions (BMLs) are important contributors to pain and progression of knee OA. There has been recent interest in bisphosphonates as a potential…
Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Anna Lafian¹, Julia Suh² and Karina Torralba³, ¹Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, ²Internal Medicine, Loma Linda University, Loma Linda, CA, ³Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
Abstract Number: 1850 • 2017 ACR/ARHP Annual Meeting
Efficacy of Zoledronic Acid and Denosumab in the Treatment of Patients with Low Back Pain and Modic Changes: A Proof of Principle Trial
Guoqi Cai¹, Laura Laslett¹, Dawn Aitken², Andrew Halliday³, Feng Pan², Petr Otahal¹, Deb Speden⁴, Tania Winzenberg¹ and Graeme Jones², ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Radiology, Royal Hobart Hospital, Hobart, Australia, ⁴Royal Hobart Hospital, Hobart, Australia
Background/Purpose: Low back pain (LBP) is a common and debilitating problem. There are currently very limited pharmacological treatments for LBP. Vertebral endplate subchondral bone abnormalities…
Abstract Number: 2390 • 2017 ACR/ARHP Annual Meeting
Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort
Stephanie Gottheil¹, Orit Schieir², Carter Thorne³, Carol A Hitchon⁴, Diane Tin⁵, Edward C. Keystone⁶, Gilles Boire⁷, Boulos Haraoui⁸, Susan J. Bartlett⁹, Vivian P. Bykerk¹⁰ and Janet E. Pope¹¹, ¹University of Western Ontario, LONDON, ON, Canada, ²McGill University, Montreal, ON, Canada, ³University of Toronto, Newmarket, ON, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Institute de Rheumatologie, Montreal, QC, Canada, ⁹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: RA patients are at a high risk of osteoporosis and fracture, in part due to frequent glucocorticoid use. Despite recommendations from ACR guidelines on…
Abstract Number: 117 • 2017 Pediatric Rheumatology Symposium
The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy
Simrat Morris^1,2, Syeda Maqsood³, Christine Garapic³, Andre Prochoroff³ and Hulya Bukulmez³, ¹Rainbow Babies and Childrens Hospital, Cleveland, OH, ²University Hospitals Cleveland Medical Center, Cleveland, OH, ³MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Individuals with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy have impaired bone health and increased fracture risk due to several factors including immobility,…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 2387 • 2016 ACR/ARHP Annual Meeting
Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis
Caroline Marie Andreasen¹, Anne Grethe Jurik², Mia Glerup³, Christian Høst⁴, Birgitte Thorsted Mahler⁴, Ellen-Margrethe Hauge⁵ and Troels Herlin⁶, ¹Dept. Rheumatology, Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Pamidronate (PAM) may be effective in diminishing pain and permanent bone deformities in chronic non-bacterial osteomyelitis (CNO). Whole body magnetic resonance imaging (WB MRI)…
Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Lucy Liu¹, Joan Lo² and Malini Chandra³, ¹Internal Medicine, Kaiser Permanente, Oakland, CA, ²Endocrinology, Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 348 • 2016 ACR/ARHP Annual Meeting
Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center
JungHee Koh¹, Seo Hwa Kim², Haneul Kim³, Min Kyung Chung³, Ji Hyeon Ju⁴ and Sung-Hwan Park⁴, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than those without, and are therefore exposed to bisphosphonates for longer. However, the increasing…
Abstract Number: 349 • 2016 ACR/ARHP Annual Meeting
Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis
Gaku Miyamura¹, Hiroki Wakabayashi², Taro Nakagawa³, Sho Kato², Yohei Naito⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu,Mie, Japan, ²Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, ³Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, ⁵Department of Orthopaedic surgery, Graduate School of Medicine, Mie University, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague lower back pain. However, there have been few reports regarding the correlation between…
Abstract Number: 317 • 2015 ACR/ARHP Annual Meeting
Relation of Incident Bisphosphonate Use to Trajectory of Joint-Space Width
Tuhina Neogi¹, Na Lu², Jingbo Niu¹, Jeffrey Duryea³ and Yuqing Zhang¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Radiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Trials regarding bisphosphonate (Bisph) effects in knee osteoarthritis (OA) have been conflicting, and are unable to provide insights into long-term effects. While Bisph may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].